157 related articles for article (PubMed ID: 9823960)
21. A new alternatively spliced exon between v9 and v10 provides a molecular basis for synthesis of soluble CD44.
Yu Q; Toole BP
J Biol Chem; 1996 Aug; 271(34):20603-7. PubMed ID: 8702806
[TBL] [Abstract][Full Text] [Related]
22. Detection of CD44 splice variants in formalin-fixed, paraffin-embedded specimens of human skin cancer.
Dietrich A; Tanczos E; Vanscheidt W; Schöpf E; Simon JC
J Cutan Pathol; 1997 Jan; 24(1):37-42. PubMed ID: 9027631
[TBL] [Abstract][Full Text] [Related]
23. HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Canella A; Cordero Nieves H; Sborov DW; Cascione L; Radomska HS; Smith E; Stiff A; Consiglio J; Caserta E; Rizzotto L; Zanesi N; Stefano V; Kaur B; Mo X; Byrd JC; Efebera YA; Hofmeister CC; Pichiorri F
Oncotarget; 2015 Oct; 6(31):31134-50. PubMed ID: 26429859
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
25. Expression of CD44 isoforms in human skin cancer.
Simon JC; Heider KH; Dietrich A; Wuttig C; Schöpf E; Adolf GR; Ponta H; Herrlich P
Eur J Cancer; 1996 Jul; 32A(8):1394-400. PubMed ID: 8869105
[TBL] [Abstract][Full Text] [Related]
26. [Expression of CD44 isoforms in normal human liver and also in regenerative and neoplastic liver changes].
Seelentag WK; Flury R; Schmid M; Komminoth P; Saremaslani P; Günthert U; Heitz PU; Roth J
Verh Dtsch Ges Pathol; 1995; 79():144-7. PubMed ID: 8600679
[TBL] [Abstract][Full Text] [Related]
27. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer.
Friedrichs K; Franke F; Lisboa BW; Kügler G; Gille I; Terpe HJ; Hölzel F; Maass H; Günthert U
Cancer Res; 1995 Nov; 55(22):5424-33. PubMed ID: 7585612
[TBL] [Abstract][Full Text] [Related]
28. Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumours.
Imam H; Eriksson B; Oberg K
Ann Oncol; 2000 Mar; 11(3):295-300. PubMed ID: 10811495
[TBL] [Abstract][Full Text] [Related]
29. Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential.
Manten-Horst E; Danen EH; Smit L; Snoek M; Le Poole IC; Van Muijen GN; Pals ST; Ruiter DJ
Int J Cancer; 1995 Jun; 64(3):182-8. PubMed ID: 7542641
[TBL] [Abstract][Full Text] [Related]
30. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor.
Stauder R; Eisterer W; Thaler J; Günthert U
Blood; 1995 May; 85(10):2885-99. PubMed ID: 7537983
[TBL] [Abstract][Full Text] [Related]
31. The influence of hormones on CD44 expression in endometrial and breast carcinomas.
Durst B; Sorg RV; Röder G; Betz B; Beckmann MW; Niederacher D; Bender HG; Dall P
Oncol Rep; 2001; 8(5):987-93. PubMed ID: 11496303
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of the human metastasis adhesion molecule CD44V in normal and carcinomatous stomach mucosa of Chinese subjects.
Harn HJ; Ho LI; Chang JY; Wu CW; Jiang SY; Lee HS; Lee WH
Cancer; 1995 Mar; 75(5):1065-71. PubMed ID: 7531611
[TBL] [Abstract][Full Text] [Related]
33. Expression of CD44 standard form and variant isoforms in human bone marrow stromal cells.
Wang X; Du Z; Liu X; Song Y; Zhang G; Wang Z; Wang Q; Gao Z; Wang Y; Wang W
Saudi Pharm J; 2017 May; 25(4):488-491. PubMed ID: 28579880
[TBL] [Abstract][Full Text] [Related]
34. Interplay between Podoplanin, CD44s and CD44v in Squamous Carcinoma Cells.
Montero-Montero L; Renart J; Ramírez A; Ramos C; Shamhood M; Jarcovsky R; Quintanilla M; Martín-Villar E
Cells; 2020 Sep; 9(10):. PubMed ID: 33003440
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: comparison with a concurrent conventional invasive carcinoma of no special type component.
Umeda T; Ishida M; Murata S; Mori T; Kawai Y; Itoi N; Tomida K; Tanaka A; Sakai S; Kitamura M; Kubota Y; Kushima R; Tani M
Breast Cancer; 2016 Nov; 23(6):869-875. PubMed ID: 26494575
[TBL] [Abstract][Full Text] [Related]
36. A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia.
Legras S; Günthert U; Stauder R; Curt F; Oliferenko S; Kluin-Nelemans HC; Marie JP; Proctor S; Jasmin C; Smadja-Joffe F
Blood; 1998 May; 91(9):3401-13. PubMed ID: 9558399
[TBL] [Abstract][Full Text] [Related]
37. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas.
Tran TA; Kallakury BV; Sheehan CE; Ross JS
Hum Pathol; 1997 Jul; 28(7):809-14. PubMed ID: 9224749
[TBL] [Abstract][Full Text] [Related]
38. Up-regulation of the tumour-associated marker CD44V6 in experimental kidney disease.
Takazoe K; Foti R; Tesch GH; Hurst LA; Lan HY; Atkins RC; Nikolic-Paterson DJ
Clin Exp Immunol; 2000 Sep; 121(3):523-32. PubMed ID: 10971520
[TBL] [Abstract][Full Text] [Related]
39. Expression of CD44 splice variants in human skin and epidermal tumours.
Seiter S; Tilgen W; Herrmann K; Schadendorf D; Patzelt E; Möller P; Zöller M
Virchows Arch; 1996 Jun; 428(3):141-9. PubMed ID: 8688968
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients.
Yousef S; Marvin J; Steinbach M; Langemo A; Kovacsovics T; Binder M; Kröger N; Luetkens T; Atanackovic D
Blood Cancer J; 2015 Mar; 5(3):e285. PubMed ID: 25747678
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
